Probably a bit off with your analysis. Keytruda is an immunotherapy drug (heading for US$10b this year) and the exercise is to investigate combination effect, which would massively enhance TT and Keytruda. TT would have a much much wider application, Keytruda would get a boost in efficacy. No one would be at loss if it goes well.
